Table 1.
Baseline demographic and clinical characteristics
| Characteristic | CRC | Non-CRC | Overall study population (N = 103) |
||||
|---|---|---|---|---|---|---|---|
| ≥ 2 Prior therapies (N = 41) | 1 Prior therapy (N = 24) | Total (N = 65) |
GC (N = 18) |
Other solid tumors (N = 20) |
Total (N = 38) |
||
| Age (years) | |||||||
| Median | 48.0 | 50.5 | 49.0 | 61.0 | 56.0 | 58.5 | 53.0 |
| Range | 25–77 | 22–76 | 22–77 | 34–72 | 36–75 | 34–75 | 22–77 |
| Sex, n (%) | |||||||
| Male | 30 (73) | 13 (54) | 43 (66) | 14 (78) | 8 (40) | 22 (58) | 65 (63) |
| Female | 11 (27) | 11 (46) | 22 (34) | 4 (22) | 12 (60) | 16 (42) | 38 (37) |
| Ethnicity, n (%) | |||||||
| Han Chinese | 39 (95) | 21 (87.5) | 60 (92) | 18 (100) | 20 (100) | 38 (100) | 98 (95) |
| Other | 2 (5) | 3 (12.5) | 5 (8) | 0 | 0 | 0 | 5 (5) |
| ECOG PS, n (%) | |||||||
| 0 | 10 (24) | 7 (29) | 17 (26) | 3 (17) | 7 (35) | 10 (26) | 27 (26) |
| 1 | 31 (76) | 17 (71) | 48 (74) | 15 (83) | 13 (65) | 28 (74) | 76 (74) |
| Cancer diagnosis, n (%) | |||||||
| Colorectal cancer | 41 | 24 | 65 | – | – | – | 65 (63) |
| Gastric/gastroesophageal junction cancer | – | – | – | 18 | – | 18 | 18 (17) |
| Other solid tumors | – | – | – | – | 20 | 20 | 20 (19) |
| Endometrial cancer | – | – | – | – | 6 | 6 | 6 (6) |
| Hepatocellular cancer | – | – | – | – | 2 | 2 | 2 (2) |
| Hepatocholangiocarcinoma | – | – | – | – | 2 | 2 | 2 (2) |
| Bladder cancer | – | – | – | – | 1 | 1 | 1 (1) |
| Cervical cancer | – | – | – | – | 1 | 1 | 1 (1) |
| Cholangiocarcinoma | – | – | – | – | 1 | 1 | 1 (1) |
| Esophageal cancer | – | – | – | – | 1 | 1 | 1 (1) |
| Non-small cell lung cancer | – | – | – | – | 1 | 1 | 1 (1) |
| Osteosarcoma | – | – | – | – | 1 | 1 | 1 (1) |
| Prostate cancer | – | – | – | – | 1 | 1 | 1 (1) |
| Renal pelvic carcinoma | – | – | – | – | 1 | 1 | 1 (1) |
| Urothelial carcinoma | – | – | – | – | 1 | 1 | 1 (1) |
| Uterine sarcoma | – | – | – | – | 1 | 1 | 1 (1) |
| Number of prior systemic treatments | |||||||
| Median | 3 | 2 | 3 | 2 | 2 | 2 | 2 |
| Range | 1–7 | 1–4 | 1–7 | 1–4 | 1–5 | 1–5 | 1–7 |
CRC with ≥ 2 prior therapies included patients previously treated with a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimen
CRC with 1 prior therapy included patients previously treated with a fluoropyrimidine- and oxaliplatin- or fluoropyrimidine- and irinotecan-containing regimen
CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; GC, gastric cancer; PS, performance status